Galectin-9 ameliorates herpes simplex virus-induced inflammation through apoptosis

Area of Science:

• Immunology
• Inflammation Research

Background:

• Tim-3, a receptor, interacts with its ligand Galectin-9 (Gal-9) to regulate T-helper 1 (Th1) immune responses.
• Elevated Tim-3 expression is observed in inflammatory conditions like rheumatoid arthritis and in a mouse model of Behcet's disease (BD).
• Gal-9 levels were found to be lower in macrophages of BD-like mice compared to healthy controls.

Purpose of the Study:

• To investigate the therapeutic potential of Galectin-9 in a herpes simplex virus-induced Behcet's disease mouse model.
• To explore the role of the Tim-3-Gal-9 interaction in modulating inflammatory symptoms.

Main Methods:

• Galectin-9 (100 μg) was administered five times at 3-day intervals to Behcet's disease-like mice.
• Changes in disease symptoms, severity scores, regulatory T cell expression, and pro-inflammatory cytokine levels were monitored over 15 days.

Main Results:

• Gal-9 treatment significantly improved inflammatory symptoms and reduced disease severity scores in the treated mice.
• Regulatory T cell expression was increased, and pro-inflammatory cytokine levels were decreased in the Gal-9-treated group compared to controls.
• The findings suggest that the Tim-3-Gal-9 interaction plays a role in influencing inflammatory symptoms.

Conclusions:

• Galectin-9 demonstrates therapeutic efficacy in mitigating inflammation in a Behcet's disease mouse model.
• The Tim-3-Gal-9 pathway is implicated in the regulation of inflammatory responses relevant to Behcet's disease.
• Targeting the Tim-3-Gal-9 interaction may offer a novel therapeutic strategy for inflammatory disorders.